Rating #101
Tom Steyer
Farallon Capital Management
Portfolio value
Stocks
Performance
1 Year
+13.55%
Stock Holdings
$
%
1Y
3Y
5Y
10Y
Tom Steyer’s Portfolio: Q4 2025
Top10 stocks: 46.85% of the portfolio
Tom Steyer’s Trades: Q4 2025
Adds
New Buys
Sold Outs
Cuts
1.45ppt
1.75ppt
1.00ppt
1.11ppt
0.97ppt
0.62ppt
0.40ppt
0.68ppt
1.51ppt
0.54ppt
Company Name | Share Count Chg. (%) | Price Paid | Buy Value | Portfolio % Change | |
|---|---|---|---|---|---|
1  BSX | Add +56.74% | $98.04 | $264.02M | 1.45ppt | |
2  AMZN | Add +28.36% | $228.79 | $227.46M | 1.75ppt | |
3  MSFT | Add +15.73% | $501.12 | $150.81M | 1.00ppt | |
4  AON | Add +17.00% | $349.16 | $135.20M | 1.11ppt | |
5  LNTH | Add +56.09% | $58.19 | $113.49M | 0.97ppt | |
6  GRAL | Add +73.66% | $86.40 | $85.85M | 0.62ppt | |
7  CAH | Add +127.67% | $188.19 | $60.79M | 0.40ppt | |
8  WAB | Add +12.29% | $205.44 | $55.65M | 0.68ppt | |
9  BBIO | Add +9.84% | $65.64 | $52.94M | 1.51ppt | |
10  CRNX | Add +20.16% | $44.52 | $51.78M | 0.54ppt |
Tom Steyer’s Holdings: Q4 2025
Company Name | Primary Industry | Avg. price paid  | Share Count Chg. (%) | No of shares held | Market value | Portfolio % Change | % of Ownership | Holding period | Last Transaction | |
|---|---|---|---|---|---|---|---|---|---|---|
- | $666.18 | Cut -11.76% | 3.00M | $2.05B | 9.65% 0.38ppt | - | 21 Quarters | Q4 2025 | ||
2  RVMD | Biological products | $35.28 | Cut -0.29% | 14.58M | $1.16B | 5.48% 2.68ppt | 7.71% | 20 Quarters | Q4 2025 | |
3 MSFT | Prepackaged Software | $340.67 | Add +15.73% | 2.21M | $1.07B | 5.05% 1.00ppt | 0.03% | 50 Quarters | Q4 2025 | |
4 AMZN | Retail-Catalog & Mail-Order | $221.93 | Add +28.36% | 4.50M | $1.04B | 4.90% 1.75ppt | 0.04% | 3 Quarters | Q4 2025 | |
5 AON | Insurance Agents & Brokers | $331.96 | Add +17.00% | 2.67M | $940.51M | 4.44% 1.11ppt | 1.24% | 23 Quarters | Q4 2025 | |
6  NTRA | Medical Laboratories | $74.68 | Cut -7.97% | 3.91M | $896.74M | 4.23% 1.43ppt | 2.85% | 19 Quarters | Q4 2025 | |
7 BSX | Surgical Instruments | $73.80 | Add +56.74% | 7.44M | $709.36M | 3.35% 1.45ppt | 0.50% | 22 Quarters | Q4 2025 | |
- | $186.11 | Cut -29.41% | 3.60M | $689.62M | 3.25% -0.71ppt | - | 6 Quarters | Q4 2025 | ||
9  EXEL | Biological products | $23.27 | Cut -19.44% | 15.71M | $688.55M | 3.25% -0.05ppt | 5.78% | 30 Quarters | Q4 2025 | |
10 BBIO | Pharmaceutical Pres | $37.26 | Add +9.84% | 9.00M | $688.29M | 3.25% 1.51ppt | 4.72% | 6 Quarters | Q4 2025 | |
11 I HYG Put | - | $80.94 | Cut -79.49% | 8.00M | $645.04M | 3.04% -9.92ppt | - | 3 Quarters | Q4 2025 | |
12  PTGX | Pharmaceutical Pres | $19.79 | Cut -0.84% | 6.14M | $536.62M | 2.53% 0.85ppt | 9.63% | 33 Quarters | Q4 2025 | |
13 WAB | Railroad Equipment | $147.51 | Add +12.29% | 2.48M | $528.50M | 2.49% 0.68ppt | 1.45% | 36 Quarters | Q4 2025 | |
14  UNH | Medical Service Plans | $456.38 | Cut -15.24% | 1.60M | $527.81M | 2.49% -0.18ppt | 0.18% | 12 Quarters | Q4 2025 | |
15  CYBR | Prepackaged Software | $446.06 | New Buy +100.00% | 1.05M | $469.72M | 2.22% 2.22ppt | 2.09% | 1 Quarter | Q4 2025 | |
16  DIS | Misc. Amusement & Recreation | $98.65 | Cut -20.64% | 4.13M | $469.41M | 2.22% -0.22ppt | 0.23% | 7 Quarters | Q4 2025 | |
17  SNPS | Prepackaged Software | $469.72 | New Buy +100.00% | 999.20K | $469.34M | 2.21% 2.21ppt | 0.62% | 1 Quarter | Q4 2025 | |
18  LLY Put | Pharmaceutical Pres | $763.00 | 0.00% | 375.00K | $403.01M | 1.90% 0.73ppt | - | 2 Quarters | Q3 2025 | |
19  TMO | Other Measuring Devices | $455.67 | Cut -49.48% | 635.69K | $368.35M | 1.74% -0.76ppt | 0.17% | 25 Quarters | Q4 2025 | |
20 LNTH | Diagnostic Substances | $78.15 | Add +56.09% | 5.43M | $361.20M | 1.70% 0.97ppt | 8.07% | 12 Quarters | Q4 2025 |
NEWSLETTER
NEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersOur content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.